Menu

X
This website is owned and maintained by the Oncidium foundation, with support from Telix Pharmaceuticals. The NOBLE registry study is sponsored by the Principal Investigator and participating expert sites around the world. Telix provided funding support and drug to support the study purpose, but is not responsible for the design, output or results which are led and controlled by the independent team running the study. 99mTc-iPSMA is authorised for investigational use only. None of the technologies described on the website have received a marketing authorisation in any jurisdiction.
Sources : www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/prostate-specific-antigen-psa-testing-prostate-cancer-screening – www.cancer.net/cancer-types/prostate-cancer/diagnosis – www.oncidiumfoundation.org/patient/prostate-cancer/ – www.ncbi.nlm.nih.gov/pmc/articles – www.snmmi.org/Patients/Procedures – www.radiopaedia.org/articles/spect-vs-pet – www.medraysintell.com/ – MEDRaysintell 2019 – Globocan: https://gco.iarc.fr/today
The information on this Website is provided for information purposes only and made available on the understanding that it does not constitute professional or expert medical advice. If you are a patient using this Website, you should seek assistance from a health care professional when interpreting these materials and applying them to your individual circumstances.
If you have any concerns about your health, consult your general practitioner. Information provided on this Website does not imply endorsement of third-party services or products and cannot provide you with health and medical advice.
Use of site is subject to the terms of use and privacy policy.
If you choose not to accept the terms and conditions of use, the website page will close instantly.